WuXi PharmaTech Forms Pre-Clinical Collaboration with Janssen
March 02, 2010 at 02:02 AM EST
WuXi PharmaTech (药明康德) has struck a two-way pre-clinical services deal with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. WuXi PharmaTech will provide toxicology and other non-clinical services to Janssen, while Janssen will help WuXi attain GLP status in its new Suzhou toxicology lab. More details... Stock Symbol: (NYSE: WX)